Upper GI 2017

Negative trials with targeted agents have substantially out numbered the positive trials (the ToGA, REGARD, and RAINBOW trials) in GAC in the past decade Major factors accounting for this negative outcome may be (1) many trials did not select the patient population based on specific target , (2) inaccurate biomarker for patient selection (i.e., HER2, FISH vs. HER2 IHC)

03/28/2017